Debates rekindled on government's stern measures on generic data fabrication

Published: 2006-10-17 07:00:00

Updated: 2006-10-17 07:00:00

The controversy over the bioequivalence data fabrication has flared again following the government's unilateral administrative measure to cancel the licenses of generic drugs without lawful procedures.

In a statement delivered to the National Assembly, the Korea Pharmaceutical Manufacturers As...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK